Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NG-Shield
- Development stage
- Preclinical
- Lead developer
- Evaxion Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NG-Shield is an AI-designed prophylactic vaccine candidate developed by Evaxion Biotech for the prevention of *Neisseria gonorrhoeae* infections. The vaccine was discovered using Evaxion's proprietary EDEN (Epitope Discovery ENgine) platform, which utilizes artificial intelligence to identify highly conserved and protective antigens from the bacterial proteome. By targeting multiple computationally selected antigens, NG-Shield aims to provide broad protection against diverse strains of gonorrhea, including multi-drug resistant (MDR) 'super-gonorrhea' strains. The program is currently in the preclinical development stage, representing a novel approach to addressing the global health threat posed by the increasing prevalence of antibiotic-resistant *Neisseria gonorrhoeae*.
- Brand names
- NG-Shield
- Other names
- mRNA-based gonorrhea vaccinemRNA gonorrhea vaccine candidate
02
Targets
FtsN (Cell division protein FtsN)MetQ (D-methionine-binding lipoprotein)
Beyond the preview
Go deeper on NG-Shield.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NG-Shield.